Direkt zum Inhalt | Direkt zur Navigation

Benutzerspezifische Werkzeuge

Sie sind hier: Startseite / Klinische Studien / Studienregister


GMALL Register

GMALL Registern/an/an/an/a

GMALL registry and biomaterial bank: biomaterial collection and prospective data collection on diagnosis, treatment and disease course of adult ALL

Status: Active

Purpose / Objectives

Primary Outcome

  • Input features and prognostic factors
  • Disease status and selected therapies
  • Course of therapy, including the overall and disease-free survival, response rate and duration of different treatments and patient subgroups
  • Data for treatment with newer forms of therapy and use of newer supportive drugs
  • Quality of life at different times
  • Therapy and late effects
  • Quality of diagnosis and treatment of ALL


Secondary Outcomes

For as many questions conduct prospective treatment studies and also to allow as many clinics participating in these studies



Acute lymphoblastic leukemia


Patient attributes



Inclusion criteria

  • acute lymphatic leukemia or
  • other leukaemias (NK cell lymphoma/leukaemia, acute biphenotypic leukaemia) or
  • Non-Hodgkin lymphomas of the following subtypes (WHO classification): Burkitt's lymphoma (including atypical Burkitt lymphoma, Burkitt-like lymphoma), diffuse large B-cell lymphomas (in particular primarily mediastinal DLBCL, DLBCL with Burkitt signature, c-myc-positive DLBCL), B-lymphoblastic lymphoma, T-lymphoblastic lymphoma, large cell anaplastic lymphoma, other NHL
  • Age ≥ 18 years
  • Written consent of the patient

Exclusion criteria


Trial design

  • Multicenter
  • Prospective


no study therapy

Documents (password protected)

Responsibilities in overall trial


National Coordinating Investigator

Dr. med. Nicola Gökbuget

Study Sites

Klinik I für Innere Medizin

Study office

  • Klinisches Studienzentrum der Klinik I für Innere Medizin Köln



Principal Investigator

Prof. Dr. med. Hans Christian Reinhardt

Contact at Site